Evidence map›Paper›PMID 19158508›Full record

ReviewCell cycle (Georgetown, Tex.)2009

Fine-tuning of nuclear-catenin by Chibby and 14-3-3.

Ken-Ichi Takemaru, Victoria Fischer, Feng-Qian Li

Open access · greenAbstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

  1. The Usher syndrome 1C protein harmonin regulates canonical Wnt signaling.Frontiers in cell and developmental biology · 2023
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Major signaling pathways in intestinal stem cells.Biochimica et biophysica acta · 2013
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ken-Ichi TakemaruDepartment of Pharmacological Sciences, SUNY at Stony Brook, Stony Brook, New York 11794-8651, USA. takemaru@pharm.stonybrook.edu
Victoria Fischer
Feng-Qian Li
Stony Brook University · US

Funding

Role of Beta-Catenin Antagonist Chibby in AdipogenesisR01DK073191 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI TAKEMARU, KEN-ICHI · 2006 to 2010
$1.5M
NIDDK NIH HHS DK07319NIDDK NIH HHS R01 DK073191
6 · The paper itself

Abstract

Chibby (Cby) is an evolutionarily conserved antagonist of beta-catenin, a central player of the canonical Wnt signaling pathway, which acts as a transcriptional coactivator. Cby physically interacts with the C-terminal activation domain of beta-catenin and blocks its transcriptional activation potential through competition with DNA-binding Tcf/Lef transcription factors. Our recent study revealed a second mechanism for Cby-mediated beta-catenin inhibition in which Cby cooperates with 14-3-3 adaptor proteins to facilitate nuclear export of beta-catenin, following phosphorylation of Cby by Akt kinase. Therefore, our findings unravel a novel molecular mechanism regulating the dynamic nucleo-cytoplasmic trafficking of beta-catenin and provide new insights into the cross-talk between the Wnt and Akt signaling pathways. Here, we review recent literature concerning Cby function and discuss our current understanding of the relationship between Wnt and Akt signaling.

Indexed as

14-3-3 ProteinsAnimalsCateninsCell NucleusHumansModels, BiologicalNuclear ProteinsProto-Oncogene Proteins c-aktSignal TransductionWnt Proteins14-3-3 ProteinsCateninsNuclear ProteinsProto-Oncogene Proteins c-aktWnt Proteins

Identifiers

PMID19158508
PMCPMC2810615
OpenAlexW2086313717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.